Drug-Like Antibody Design Against Challenging Targets with Atomic Precision
10:00 am - Wednesday 26th August 2026
- Chai successfully designs antibodies against a range of therapeutically relevant, challenging targets, achieving high binding hit rates with at most 96 designs per target, where the large majority also meet developability profiles on par with clinical-stage therapeutic antibodies
- Experimentally determined structures of Chai-designed antibodies match their in silico predictions with sub-Angstrom accuracy while differentiating in sequence and structure from existing binders, demonstrating that de novo design can now deliver atomically accurate models of novel molecules
- Case studies including functional antibodies that mediate GPCR agonism, and highly specific antibodies that selectively discriminate cancer neoepitopes, demonstrate how de novo design is opening up creative, targeted therapeutic strategies beyond accelerating drug discovery
